title: Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.
abstract: Epidermal growth factor receptor (EGFR) plays a key role in tumour evolution, proliferation and immune evasion, and is one of the most important targets for biological therapy, especially for non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC). In the past 15 years, several EGFR antagonists have been approved for the treatment of NSCLC and metastatic CRC (mCRC). To optimise the use of anti-EGFR agents in clinical practice, various clinical and molecular biomarkers have been investigated, thus moving their indication from unselected to selected populations. Nowadays, anti-EGFR drugs represent a gold-standard therapy for metastatic NSCLC harbouringEGFRactivating mutation and forRASwild-type mCRC. Their clinical efficacy is limited by the presence of intrinsic resistance or the onset of acquired resistance. In this review, we provide an overview of the antitumour activity of EGFR inhibitors in NSCLC and CRC and of mechanisms of resistance, focusing on the development of a personalised approach through 15 years of preclinical and clinical research.
authors.affiliation: Division of Medical Oncology, 'F. Magrassi A. Lanzara' Department of Clinical and Experimental Medicine and Surgery , Second University of Naples, School of Medicine , Naples , Italy.
authors.forename: Teresa
authors.initials: T
authors.lastname: Troiani
authors.affiliation: Division of Medical Oncology, 'F. Magrassi A. Lanzara' Department of Clinical and Experimental Medicine and Surgery , Second University of Naples, School of Medicine , Naples , Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Napolitano
authors.affiliation: Division of Medical Oncology, 'F. Magrassi A. Lanzara' Department of Clinical and Experimental Medicine and Surgery , Second University of Naples, School of Medicine , Naples , Italy.
authors.forename: Carminia Maria
authors.initials: CM
authors.lastname: Della Corte
authors.affiliation: Division of Medical Oncology, 'F. Magrassi A. Lanzara' Department of Clinical and Experimental Medicine and Surgery , Second University of Naples, School of Medicine , Naples , Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Martini
authors.affiliation: Division of Medical Oncology, 'F. Magrassi A. Lanzara' Department of Clinical and Experimental Medicine and Surgery , Second University of Naples, School of Medicine , Naples , Italy.
authors.forename: Erika
authors.initials: E
authors.lastname: Martinelli
authors.affiliation: Division of Medical Oncology, 'F. Magrassi A. Lanzara' Department of Clinical and Experimental Medicine and Surgery , Second University of Naples, School of Medicine , Naples , Italy.
authors.forename: Floriana
authors.initials: F
authors.lastname: Morgillo
authors.affiliation: Division of Medical Oncology, 'F. Magrassi A. Lanzara' Department of Clinical and Experimental Medicine and Surgery , Second University of Naples, School of Medicine , Naples , Italy.
authors.forename: Fortunato
authors.initials: F
authors.lastname: Ciardiello
keywords: CRC; EGFR; NSCLC; resistance